HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial
16 Articles
16 Articles
The Union Democrat
HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial
Oral HBI-8000 plus intravenous nivolumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with nivolumab alone, reducing the risk of disease progression or death by 27%Median progression-free survival was 11.7 months with HBI-8000 plus nivolumab compared…
(Adnkronos) - A pill that can strip the tumor away to make it more visible to the immune system has proved to be a promising new weapon against advanced melanoma. The addition of the innovative HBI-8000 tablet drug to standard nivolumab immunotherapy demonstrates a significantly greater efficacy than monotherapy alone: it reduces the risk of the disease progressing by 27% [...]
Rec News | Lontani dal mainstream
notizie.it(Adnkronos) * A pill capable of removing the tumor to make it more visible to the immune system has proved to be a promising new weapon against advanced melanoma. * The addition of the innovative HBI-8000 tablet drug to standard nivolumab immunotherapy demonstrates in fact a significantly greater efficacy than monotherapy alone: it reduces by 27% the risk that the disease progresses [...] L'articolo Melanoma, the new pill "displaces the advanced…
The results of a new therapeutic combination that reduces the risk of disease progression in patients with advanced melanoma This article Melanoma, the new pill that slows tumor growth by 27% comes from LaPresse
Coverage Details
Bias Distribution
- 92% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
